Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2010-12-17
pubmed:databankReference
pubmed:abstractText
The authors recently reported on efficacy and safety of prolonged-release melatonin formulation (PRM; Circadin 2? mg) in elderly insomnia patients. The age cut-off for response to PRM and the long-term maintenance of efficacy and safety were further evaluated by looking at the total cohort (age 18-80 years) from that study and subsets of patients aged 18-54 and 55-80 years (for whom the drug is currently indicated).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1473-4877
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
87-98
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response.
pubmed:affiliation
CPS Research, Glasgow, UK. alangwade@fastmail.fm
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't